Pan-Ubiquitin Antibody: Foundational PTM Reagent for Ubiquitin-Proteasome and PROTAC Mechanism Research
Core Definition & Biological Significance of Ubiquitination Post-Translational Modification
Ubiquitination represents a reversible lysine-targeted post-translational modification governing nearly all core eukaryotic cellular activities including cell cycle progression, apoptotic signaling, DNA damage repair and metabolic homeostasis. The modification cascade relies on sequential E1 activating, E2 conjugating and E3 ligase enzymatic reactions to covalently attach 76-amino-acid ubiquitin polypeptides onto substrate lysine residues. Distinct ubiquitin chain topologies (K48, K63, M1) trigger divergent downstream cellular outputs: K48-linked polyubiquitin chains mark substrates for 26S proteasomal degradation, while K63 assemblies mediate kinase signaling and immune receptor trafficking. Dysregulated ubiquitin editing drives malignant transformation, neurodegenerative protein aggregation and inflammatory pathway hyperactivation, making pan-ubiquitin detection reagents indispensable for basic proteostasis research pipelines.
Core Functional Logic of Pan-Ubiquitin Broad-Spectrum Antibodies
Unlike substrate-specific antibodies targeting single modified protein sequences, pan-ubiquitin recombinant antibodies recognize conserved structural epitopes shared by free monomeric ubiquitin and all polyubiquitin chain configurations across eukaryotic proteomes. This universal binding capacity eliminates sequence bias during preliminary proteome-wide ubiquitination screening workflows. Researchers deploy pan-ubiquitin antibodies to rapidly compare global ubiquitination fluctuations between compound-treated and control cell lysates prior to targeted mass spectrometry validation. The antibody’s cross-species reactivity enables consistent profiling across human, mouse and primate cell and tissue biospecimens without separate reagent optimization for each experimental model organism.
Representative Research Case Studies Utilizing Pan-Modification Ubiquitin Antibodies
Multiple peer-reviewed preclinical projects demonstrate pan-ubiquitin antibody’s indispensable screening value across diverse disease model systems. Renal carcinoma hypoxia research employs pan-ubiquitin WB profiling to detect dose-dependent elevation of global ubiquitination under prolonged oxygen deprivation, guiding subsequent LC-MS identification of YTHDC1 modified substrates driving tumor proliferation. Acute myeloid leukemia mechanistic studies utilize pan-ubiquitin reagents to measure elevated succinylation and ubiquitination levels after SIRT5 genetic ablation, uncovering disrupted fatty acid oxidation regulatory circuits. Myocardial ischemia-reperfusion injury assays track ubiquitination shifts via pan-antibody staining to quantify cardioprotective effects of dexmedetomidine treatment linked to MDH2 modified protein stabilization.
Standardized Experimental Protocols for Reliable Pan-Ubiquitin Detection
Four standardized technical adjustments eliminate non-specific background signals during pan-ubiquitin antibody incubation workflows. Sample lysis buffers must be supplemented with DUB inhibitor cocktails such as NEM to prevent in vitro ubiquitin chain truncation during tissue homogenization. Proteasome inhibitors like MG132 may be added to culture media pre-harvest to accumulate low-abundance degradative ubiquitinated substrates for improved band visibility. Serial antibody dilution titrations define optimal working concentrations for WB, IHC and ICC formats to balance signal intensity and background noise. Dual reference loading controls (total histone or GAPDH) normalize ubiquitination band intensities to correct uneven sample input across gel lanes. Parallel knockout cell negative controls validate antibody epitope specificity and rule out off-target polypeptide cross-recognition artifacts.
Pan-Ubiquitin Antibody Applications in PROTAC Targeted Degradation Research
The emergence of proteolysis-targeting chimeras (PROTAC) expands the core research demand for validated pan-ubiquitin detection reagents. PROTAC bifunctional molecules recruit endogenous E3 ligases to induce target protein K48 polyubiquitination and proteasomal clearance. Pan-ubiquitin antibodies enable semi-quantitative Western blot assessment of induced substrate ubiquitination following compound treatment time series. Immunoprecipitation coupled with pan-ubiquitin enrichment captures modified target protein complexes for mass spectrometry chain linkage identification. Tissue immunohistochemistry utilizing pan-ubiquitin antibodies visualizes in vivo target degradation gradients within xenograft tumor lesions after systemic PROTAC administration. Parallel pan-ubiquitin profiling screens compound library candidates to prioritize molecules capable of robust substrate ubiquitination induction.
S0B0087 Pan-Ubiquitin Recombinant mAb Performance Specifications
ANT BIO PTE. LTD. Ubiquitin Recombinant Rabbit mAb (Catalog S0B0087, Clone SDT-R095) is manufactured via proprietary S-RMab single B cell recombinant antibody technology. Rigorous multi-platform validation confirms uniform recognition of free ubiquitin, K48/K63 polyubiquitin chains across human and murine proteomic samples. Peptide competition assays verify negligible cross-reactivity against acetyl, lactyl and succinyl lysine PTM epitopes to eliminate off-target band interference. Protein A chromatographic purification delivers ≥95 antibody purity with endotoxin concentrations controlled below 1.0 EU/μg for cellular co-culture functional assays. Standardized validated dilutions include WB 1:1000, FFPE IHC 1:2000 and intracellular ICC 1:500 for streamlined multi-assay experimental setup. Consistent lot-to-lot signal uniformity supports long-term serial tissue microarray and compound cohort screening campaigns.
Diversified Fundamental Research Workflows Supported by S0B0087 Antibody
Oncogenic proteostasis research utilizes pan-ubiquitin WB to profile global ubiquitination shifts after E3 ligase or DUB inhibitor compound incubation cycles. Neurodegeneration mechanism IHC stains brain tissue sections to quantify aggregated ubiquitinated protein inclusion bodies within disease model neurons. PROTAC drug candidate validation combines pan-ubiquitin immunoprecipitation and LC-MS to map substrate polyubiquitin chain topology dynamics. DNA damage repair co-culture assays track rapid ubiquitination of ATM and BRCA repair factors post irradiation stimulation. Multiplex immunofluorescence co-staining pairs pan-ubiquitin antibodies with lineage biomarkers to resolve cell-type specific proteostasis defects within heterogeneous tumor and inflammatory tissue microdomains.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANT BIO PTE. LTD., we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.
